Merck & Co., Inc.

NYSE:MRK

Drug Manufacturers - General

Healthcare
$137.78 -1.14%

-$1.32 today

Market cap
$339.66B
Beta
0.22
P/E (TTM)
31.6
EPS (TTM)
$3.61
Dividend yield
2.94%
52W Low $76.66High $125.14

Volume 9.69M

Average 11.85M

MRK EBITDA Margin

EBITDA as a percentage of revenue.

Merck & Co., Inc.NYSE: MRK

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin narrows to 8.6%

EBITDA Margin was 8.6% in Q2 FY2026, down 32.1 pp from a year earlier. On a trailing-twelve-month basis it was 21.0%, down 18.3 pp year over year. Over 3 fiscal years it widened by 7.6 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 18 analysts of 23.9% for the fiscal year ending Dec 2026, down from 43.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
8.6%+21.0 pp QoQ
Last fiscal yearDec 2025
43.5%+3.5 pp YoY
LTMJun 2026
21.0%-18.3 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-32.1 pp+4.2 pp+36.3 pp
1 year+3.5 pp-19.6 pp-23.1 pp
3 years+7.6 pp+9.9 pp+2.4 pp
5 years+9.2 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
43.5%
Year-over-year change
+3.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How MRK compares with its peers on the latest reported figures

  • MRK's LTM Jun 2026 EBITDA Margin of 21.0% is the 9th highest of the 10 companies compared; the peer median is 34.4%.
  • Its year-over-year change of -18.3 pp is the 9th highest of 10, against a peer median of +0.6 pp.
  • Over three fiscal years its change of +7.6 pp compares with a peer median of +8.2 pp.
MRK Competitors Peer median
EBITDA Margin for MRK and competitors
Company Period LTM level YoY 3-year change
LLYEli Lilly and CompanyLTM Jun 202654.4% +14.4 pp+18.3 pp
AMGNAmgen Inc.LTM Jun 202646.2% +0.7 pp-0.2 pp
NVSNovartis AGLTM Jun 202640.0% -1.1 pp+8.2 pp
ABBVAbbVie Inc.LTM Sep 202636.6% +15.1 pp-12.8 pp
AZNAstraZeneca PLCLTM Sep 202634.4% +3.4 pp+13.3 pp
JNJJohnson & JohnsonLTM Sep 202631.0% -11.9 pp+10.3 pp
SNYSanofiLTM Jun 202630.2% +0.6 pp-6.6 pp
PFEPfizer Inc.LTM Jun 202621.2% -10.4 pp-13.7 pp
MRKMerck & Co., Inc.LTM Jun 202621.0% -18.3 pp+7.6 pp
GILDGilead Sciences, Inc.LTM Jun 20264.4% -33.6 pp+13.7 pp
Peer median (excluding MRK) 34.4%+0.6 pp+8.2 pp

Competitors are the stored peer set for MRK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.7B59.28B60.12B64.17B64.93B
Cost of Revenue13.63B17.41B16.13B15.19B18.2B
Gross Profit35.08B41.87B43.99B48.98B46.73B
Gross Margin72.0%70.6%73.2%76.3%72.0%
Research & Development12.25B13.55B30.53B17.94B12.51B
Selling, General & Admin9.4B9.67B9.88B10.1B10.73B
Operating Expenses21.88B23.59B41.04B28.75B23.25B
Depreciation & Amortization3.21B3.91B3.87B4.5B5.84B
EBITDA17.9B21.32B6.91B25.71B28.26B
EBITDA Margin36.8%36.0%11.5%40.1%43.5%
Operating Income13.2B18.28B2.95B20.22B23.49B
Operating Margin27.1%30.8%4.9%31.5%36.2%
Interest Income36M157M365M415M343M
Interest Expense806M962M1.15B1.27B1.36B
Other Income / Expenses680M(1.84B)(1.07B)(285M)(2.42B)
Income Before Tax13.88B16.44B1.89B19.94B21.07B
Pre-Tax Margin28.5%27.7%3.1%31.1%32.4%
Income Tax Expense1.52B1.92B1.51B2.8B2.8B
Net Income13.05B14.52B365M17.12B18.25B
Net Margin26.8%24.5%0.6%26.7%28.1%
EPS (Basic)5.165.730.146.767.30
EPS (Diluted)5.145.710.146.747.28
Weighted Avg Shares2.53B2.53B2.55B2.53B2.5B
Weighted Avg Shares (Diluted)2.54B2.54B2.55B2.54B2.51B

Merck & Co., Inc.

NYSE:MRK

Intrinsic Alpha fair value

Locked

Current Price

$137.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.